Citations

Clear

1320 citation(s) found for "Nguyen, Vi".

Landmark Cancer Clinical Trials and Real-World Patient Populations: Examining Race and Age Reporting
Jayakrishnan, Thejus , Baksh, Mizba , Nguyen, Kianna M. , Ailawadhi, Meghna, Samreen, Ayesha , Sher, Taimur , Paulus, Aneel , Chanan‐Khan, Asher , Baksh, Mizba , Nguyen, Kianna, Samreen, Ayesha , Paulus, Aneel , Chanan-Khan, Asher, Nguyen, Kianna M , Aulakh, Sonikpreet , Parrondo, Ricardo D , Roy, Vivek , Manochakian, Rami , Ailawadhi, Sikander

Mayo Clinic

Cancers | November 18, 2021 | Volume: 13 | Issue: 22 | Pages: 5770

10.3390/cancers13225770 | PMID 34830924 Get It

Background: Concern exists that the clinical trial populations differ from respective cancer populations in terms of their age distribution affecting the generalizability of the results, especially in underrepresented minorities. We hypothesized that the clinical trials that do not report race are likely to suffer from a higher degree of age disparity. Methods: Food and Drug Administration (FDA) drug approvals from July 2007 to June 2019 were reviewed to identify oncology approvals, and trials with age details were selected. The outcomes studied were the weighted mean difference in age between the clinical trial population and real-world population for various cancers, the prevalence of race reporting and association of age and race reporting with each other. Results: Of the 261 trials, race was reported in 223 (85.4%) of the trials, while 38 trials (14.6%) had no mention of race. Race reporting improved minimally over time: 29 (85.3%) in 2007–2010 vs. 49 (80.3%) in 2011–2014 vs. 145 (85.4%) during the period 2015–2019 (p-value = 0.41). Age discrepancy between the clinical trial population and the real-world population was higher for studies that did not report race (mean difference −8.8 years (95% CI −12.6 to −5.0 years)) vs. studies that did report it (mean difference −5.1 years, (95% CI −6.4 to −3.7 years), p-value = 0.04). Conclusion: The study demonstrates that a significant number of clinical trials leading to cancer drug approvals suffer from racial and age disparity when compared to real-world populations, and that the two factors may be interrelated. We recommend continued efforts to recruit diverse populations.
NCOG-12. COGNITIVE FUNCTION (CF) & QUALITY OF LIFE (QOL) IN PATIENTS TREATED WITH PROCARBAZINE, CCNU, & VINCRISTINE (PCV) + RADIOTHERAPY (RT) VS. RT FOR ANAPLASTIC OLIGODENDROGLIOMA (AO) ON NRG RTOG TRIAL 9402
Won, Minhee , Cairncross, J. Gregory , Buckner, Jan C. , Fink, Karen, Bahary, Jean-Paul , Hartford, Alan C. , Souhami, Luís, Nguyen, Timothy K., Cescon, Terrence P., Pu, Anthony T. , Roa, Wilson , Polley, M.Y., Donovan, Laura, IWAMOTO, FABIO MASSAITI , Mishra, Mark V. , Barani, Igor J. , Huang, Jiayi , Mehta, Minesh P.

Mayo Clinic

Neuro-Oncology | November 18, 2021 | Volume: 23 | Issue: Supplement_6 | Pages: vi154-vi154

10.1093/neuonc/noab196.603 Get It

Abstract BACKGROUND PCV+RT substantially prolongs survival in AO patients, but long-term CF and QOL implications are unclear. We compared CF and QOL by treatment arm in RTOG 9402 participants and evaluated the impact that baseline characteristics had on CF, QOL, and survival. METHODS CF and QOL were evaluated using the Mini Mental State Exam (MMSE) and Brain-Quality of Life (B-QOL) scale at baseline and annually. Scores were analyzed between treatment arms at each time point for patients with ≥ 10 years of follow-up data. Shared parameter models evaluated MMSE and B-QOL scores and survival for all patients. RESULTS 42/148 (28.4%) participants in PCV+RT and 20/143 (14%) in RT alone arms survived ≥ 10 years. 35/42 and 39/42 (PCV+RT) and 18/20 and 17/20 (RT) participants completed baseline B-QOL and MMSE assessments, respectively. B-QOL scores did not differ between treatment groups at any time-point. Among 16 patients (10 PCV+RT, 6 RT) who completed year 10 MMSE evaluations, mean MMSE score at 10 years was higher in the RT arm (29.83 [95% CI 22.1, 30.0] vs. 26.50 [95% CI 29.4, 30.0], P= 0.04). Change in MMSE and B-QOL scores from baseline did not differ significantly between treatment groups at any time. In shared parameter models including all patients with baseline assessments, MMSE and B-QOL scores decreased over time (MMSE P= 0.0189, B-QOL P= 0.0005), but this did not differ by treatment group (MMSE P= 0.5727, B-QOL P= 0.3592). Younger age and higher KPS predicted better scores (MMSE P < 0.0001, P = 0.0002; B-QOL P = 0.0043, P = 0.0007). PCV+RT predicted better survival in both models. CONCLUSIONS PCV+RT improves survival in AO. Shared parameter models show decrease in MMSE and B-QOL over time. However, relative to RT alone, the addition of PCV did not impact change in CF and QOL over time.
Ex Vivo and In Vivo CD46 Receptor Utilization by Species D Human Adenovirus Serotype 26 (HAdV26)
Hemsath, Jack R. , Liaci, A. Manuel , Rubin, Jeffrey D. , Parrett, Brian J. , Lu, Shao‐Chia , Turner, Mallory A., Chen, Christopher Y. , Cupelli, Karolina, Reddy, Vijay , Stehle, Thilo , Liszewski, M. Kathryn , Atkinson, John P. , Barry, Michael A. , Stehle, Thilo , Barry, Michael A , Nguyen, Tien Anh

Mayo Clinic

Journal of Virology | November 17, 2021 | Volume: 96 | Issue: 3 | Pages: No page available

10.1128/jvi.00826-21 | PMID 34787457 Get It

The human species D Ad26 is being investigated as a low-seroprevalence vector for oncolytic virotherapy and gene-based vaccination against HIV-1 and SARS-CoV-2. However, there is debate in the literature about its tropism and receptor utilization, which directly influence its efficiency for certain applications. This work was aimed at determining which receptor(s) this virus uses for infection and its role in virus biology, vaccine efficacy, and, importantly, vaccine safety.
PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and 68Ga‐PSMA‐11 PET Using Cyclotron‐Produced 68Ga
Thompson, Scott M. , Suman, Garima , Chen, Zongming E., Jondal, Danielle E. , Patra, Anurima , Ehman, Eric C. , Andrews, James C. , Fleming, Chad J. , Welch, Brian T. , Kurup, A. Nicholas , Roberts, Lewis R. , Watt, Kymberly D. , Truty, Mark J. , Smoot, Rory L. , Yin, Jun , Jacobson, Mark, Kemp, Bradley J. , Venkatesh, Sudhakar K. , Johnson, Geoffrey B. , Woodrum, David A. , Goenka, Ajit H. , Chen, Zong-ming E., Kurup, Anil N, Watt, K D , Cleary, Sean P. , Wang, Chen , Fogarty, Zachary C , Venkatesh, Sudhakar K , Roberts, Lewis R , Smoot, Rory L , Johnson, Geoffrey B , Kurup, Anil N , Thompson, Scott , Torbenson, Michael , Heimbach, Julie K. , Tran, Nguyen H. , Mahipal, Amit , Zemla, Tyler , Wang, Chen , Fogarty, Zachary C.

Mayo Clinic

Hepatology Communications | November 16, 2021 | Volume: 6 | Issue: 5 | Pages: 1172-1185

10.1002/hep4.1861 | PMID 34783177 Get It

Prostate‐specific membrane antigen (PSMA) is a validated target for molecular diagnostics and targeted radionuclide therapy. Our purpose was to evaluate PSMA expression in hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), and hepatic adenoma (HCA); investigate the genetic pathways in HCC associated with PSMA expression; and evaluate HCC detection rate with 68Ga‐PSMA‐11 positron emission tomography (PET). In phase 1, PSMA immunohistochemistry (IHC) on HCC (n = 148), CCA (n = 111), and HCA (n = 78) was scored. In a subset (n = 30), messenger RNA (mRNA) data from the Cancer Genome Atlas HCC RNA sequencing were correlated with PSMA expression. In phase 2, 68Ga‐PSMA‐11 PET was prospectively performed in patients with treatment‐naïve HCC on a digital PET scanner using cyclotron‐produced 68Ga. Uptake was graded qualitatively and semi‐quantitatively using standard metrics. On IHC, PSMA expression was significantly higher in HCC compared with CCA and HCA (P < 0.0001); 91% of HCCs (n = 134) expressed PSMA, which principally localized to tumor‐associated neovasculature. Higher tumor grade was associated with PSMA expression (P = 0.012) but there was no association with tumor size (P = 0.14), fibrosis (P = 0.35), cirrhosis (P = 0.74), hepatitis B virus (P = 0.31), or hepatitis C virus (P = 0.15). Overall survival tended to be longer in patients without versus with PSMA expression (median overall survival: 4.2 vs. 1.9 years; P = 0.273). FGF14 (fibroblast growth factor 14) mRNA expression correlated positively (rho = 0.70; P = 1.70 × 10‐5) and MAD1L1 (Mitotic spindle assembly checkpoint protein MAD1) correlated negatively with PSMA expression (rho = −0.753; P = 1.58 × 10‐6). Of the 190 patients who met the eligibility criteria, 31 patients with 39 HCC lesions completed PET; 64% (n = 25) lesions had pronounced 68Ga‐PSMA‐11 standardized uptake value: SUVmax (median [range] 9.2 [4.9‐28.4]), SUVmean 4.7 (2.4‐12.7), and tumor‐to‐liver background ratio 2 (1.1‐11). Conclusion: Ex vivo expression of PSMA in neovasculature of HCC translates to marked tumor avidity on 68Ga‐PSMA‐11 PET, which suggests that PSMA has the potential as a theranostic target in patients with HCC.
Optimizing Chemotherapy Choice in the Treatment of Advanced Pancreatic Cancer—It Is Complicated
Bekaii‐Saab, Tanios , Bekaii-Saab, Tanios S , Tran, Nguyen H.

Mayo Clinic

JAMA Network Open | November 15, 2021 | Volume: 4 | Issue: 11 | Pages: e2134458

10.1001/jamanetworkopen.2021.34458 | PMID 34779853 Get It

Correlation between workload and teamwork among residents in DIEP Flap surgery
Wang, Tianke , Harless, Christin A., Nguyen, Minh-Doan T. , Norasi, Hamid , Law, Katherine E. , Hallbeck, M. Susan

Mayo Clinic

Proceedings of the Human Factors and Ergonomics Society Annual Meeting | November 12, 2021 | Volume: 65 | Issue: 1 | Pages: 1210-1214

10.1177/1071181321651083 Get It

The goal of this study was to evaluate residents’ workload and teamwork and the correlation between their workload and teamwork subscales during deep inferior epigastric perforator (DIEP) flap surgery. Ten residents who assisted during DIEP flap procedures completed an electronic survey following each DIEP flap procedure from July 2019 to August 2020. The survey contained items from the NASA-TLX and SURG-TLX and questions to measure teamwork subscales. Across 29 surgical cases, 38 surveys were recorded. Overall, the means of workload subscales were mostly greater than 10 and less than 15 (range=020) and the means of all teamwork subscales were greater than 15 (range=0-20). Good teamwork was correlated with lower distractions (Rs= -0.36 to -0.48) and better performance (Rs=0.35 to 0.52). Also, all the teamwork subscales were highly correlated (Rs= 0.59 to 0.92). Our findings suggest that good teamwork, low distractions, and successful performance are generally observed together; however, a causative relationship could not be established based on these results.
Mortality from snakebite envenomation: an analysis from the Global Burden of Disease Study 2019
Roberts, Nicholas L S , Johnson, Emily K. , Zeng, Scott , Hamilton, Erin B, Alahdab, Fares , Alipour, Vahid, Andrei, Cătălina Liliana , Arabloo, Jalal , Badiye, Ashish , Bakkannavar, Shankar M , Bhalla, Ashish, Bijani, Ali , Cai, Tianji , Carvalho, Félix , Chu, Dinh‐Toi , Couto, Rosa A S, Desta, Abebaw Alemayehu, Earl, Lucas, Eftekhari, Aziz , Esmaeilzadeh, Firooz , Gebregiorgis, Birhan Gebresillassie , Ghashghaee, Ahmad , Golechha, Mahaveer , Haque, Syed Arefinul , Kapoor, Neeti , Khan, Ejaz Ahmad , Khundkar, Roba , Krishan, Kewal , Kumar, G Anil , Lim, Stephen S , Manafi, Navid , Miller, Ted R. , Mokdad, Ali A, Monteiro, Francis N.P., Moradi, Maryam , Nguyen, Cuong Tat , Nguyen, Huong Lan Thi , Ostroff, Samuel M, Pham, Hai Quang , Rabiee, Navid , Rao, Sowmya R. , Rawaf, David Laith , Reiner, Robert C. , Samy, Abdallah M , Sawhney, Monika, Schwebel, David C. , Senthilkumaran, Subramanian , Shaikh, Masood Ali , Tovani‐Palone, Marcos Roberto , Travillian, Ravensara S., Velazquez, Diana Zuleika , Zhang, Zhi‐Jiang , Naghavi, Mohsen , Dandona, Rakhi , Dandona, Lalit , James, Spencer L , Murray, Christopher, Hay, Simon I , Vos, Theo , Abdoli, Amir , Ancuceanu, Robert , Anvari, Davood , Ausloos, Marcel , Awedew, Atalel Fentahun , Bhardwaj, Nikha , Bhardwaj, Pankaj , Bhaumik, Soumyadeep , Boloor, Archith , Dai, Xiaochen , Do, Hoa , Farzadfar, Farshad , Fernandes, Eduarda , Filip, Irina , Foroutan, Masoud , Franklin, Richard C. , Gaidhane, Abhay Motiramji , Gebremichael, Berhe , Hamidi, Samer , Haque, Syed, Hayat, Khezar , Herţeliu, Claudiu , Ilesanmi, Olayinka Stephen , Islam, M. Mofizul , Jagnoor, Jagnoor , Kanchan, Tanuj , Khatib, Mahalaqua Nazli , Kumar, Nithin , Landires, Iván , Madadin, Mohammed , Maled, Venkatesh , Marczak, Laurie B. , Menezes, Ritesh G. , Meretoja, Tuomo J , Mohammadian-Hafshejani, Abdollah , Nayak, Vinod C , Núñez-Samudio, Virginia , Padubidri, Jagadish Rao , Pinheiro, Marina , Pirestani, Majid , Zahiruddin, Quazi Syed , Radfar, Amir , Rahimi‐Movaghar, Vafa , Rastogi, Prateek , Rawaf, Salman , Sahebkar, Amirhossein , Skryabin, Valentin Yurievich , Skryabina, Anna Aleksandrovna , Soheili, Amin , Stokes, Mark Andrew , Thapar, Rekha , Tran, Bach Xuan , Pigott, David M. , Ong, Sok King , Alahdab, Fares

Mayo Clinic

No container title available | November 9, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1021472/v1 Get It

Abstract Venomous snakebite is an important cause of preventable death. The World Health Organization (WHO) set a goal to halve snakebite mortality by 2030. We used verbal autopsy and vital registration data to model the proportion of venomous animal deaths due to snakes by location, age, year, and sex, and applied these proportions to venomous animal contact mortality estimates from the Global Burden of Disease 2019 study. In 2019, 63,400 people (95% uncertainty interval 38,900–78,600) died globally from snakebites, which was equal to an age-standardized mortality rate (ASMR) of 0.8 deaths (0.5–1.0) per 100,000 and represents a 36% (2–49) decrease in ASMR since 1990. India had the greatest number of deaths in 2019, equal to an ASMR of 4.0 per 100,000 (2.3-5.0). We forecast mortality will continue to decline, but not sufficiently to meet the WHO’s goals. Improved data collection should be prioritized to help target interventions, improve burden estimation, and monitor progress.
518 First-in-human results with the novel tumor-targeting antibody ATRC-101: phase 1b study in patients with solid tumors
Powderly, John D. , Xing, Yan , Weroha, S. John , Doroshow, Deborah B. , Valdes-Albini, Frances , Millward, Carl, Walter, Kimberly, Wrong, Andrew, Castillo, Paul Del, Whidden, Mark, Isakoff, Steven J. , Jones, Jeremy C , Bekaii‐Saab, Tanios , Ulahannan, Susanna Varkey , Wang, Lixia , Nguyen, Ngan Thi Kim , Benjamin, Jonathan

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 9, 2021 | Volume: No volume available | Issue: No issue available | Pages: A548-A548

10.1136/jitc-2021-sitc2021.518 Get It

Feto-Maternal Outcomes of Breastfeeding during Pregnancy: A Systematic Review and Meta-Analysis
Ghozy, Sherief , Hashan, Mohammad Rashidul , Linh, Le Khac , Abdelrahman, Sara Attia Mahmoud , Tran, Quynh Thuy Huong , Quan, Nguyen Khoi , Le, Tran , Ibrahim, Hassan Yousif, El-Nile, Mohamed Omar, Kamel, Ahmed Mostafa Ahmed , Huy, Nguyen Tien , Giang, Hoang Thi Nam , Huy, Nguyen Tien , Ghozy, Sherief , Minh, Le Huu Nhat , Tawfik, Gehad Mohamed , Nam, Nguyen Hai

Mayo Clinic

Journal of Tropical Pediatrics | November 5, 2021 | Volume: 67 | Issue: 6 | Pages: No page available

10.1093/tropej/fmab097 | PMID 34962568 Get It

Abstract Background Breastfeeding is beneficial to both mother and infant. However, overlap of lactation with pregnancy and short recuperative intervals may impact mothers nutritionally. We aimed to investigate the possible effects of pregnancy during breastfeeding. Methods In October 2018, we searched systematically in nine electronic databases to investigate any association of breastfeeding during pregnancy with fetal and/or maternal outcomes. The study protocol was registered in PROSPERO (CRD41017056490). A meta-analysis was done to detect maternal and fetal outcomes and complications during pregnancy. Quality assessment was performed using the Australian Cancer Council bias tool for included studies. Results With 1992 studies initially identified, eight were eligible for qualitative analysis and 12 for quantitative analysis. Our results showed no significant difference in different abortion subtypes between lactating and non-lactating ones. In delivery, no difference between two groups regarding the time of delivery in full-term healthy, preterm delivery and preterm labor. No significant difference was detected in rates of antepartum, postpartum hemorrhage and prolonged labor between two groups. The women with short reproductive intervals may have higher supplemental intake and greater reduction fat store. The present studies showed that breastfeeding during pregnancy does not lead to adverse outcomes in the mother and her fetus in normal low-risk pregnancy, although it may lead to the nutritional burden on the mother. Conclusion The present studies showed that breastfeeding during pregnancy did not lead to the adverse outcomes in the mother and her fetus.
The Goldilocks Procedure with and without Implant-Based Immediate Breast Reconstruction in Obese Patients: The Mayo Clinic Experience
Bustos, Samyd S. , Nguyen, Minh-Doan T., Harless, Christin A., Tran, Nho V. , Martinez‐Jorge, Jorys, Lin, Jason , Forte, Antonio J. , Casey, William J., McLaughlin, Sarah A. , Gray, Richard J. , Manrique, Oscar J. , Nguyen, Minh-Doan, Forte, Antonio Jorge , Bustos, S S , Nguyen, Minh-Doan T. , Boughey, Judy C.

Mayo Clinic

Plastic & Reconstructive Surgery | October 28, 2021 | Volume: 148 | Issue: 4 | Pages: 703-716

10.1097/prs.0000000000008362 | PMID 34550922 Get It

Background: Obesity is a risk factor for complications in breast reconstruction. Thus, implant-based immediate breast reconstruction in obese women may be controversial. The authors analyzed obese patients who underwent skin-sparing mastectomy using Wise-pattern incisions (Goldilocks procedure) and compared outcomes between two groups: Goldilocks with immediate breast reconstruction and Goldilocks only. Methods: A retrospective review was performed of patients with a body mass index of 30 kg/m2 or higher who underwent the Goldilocks procedure at the Mayo Clinic Health System from 2012 to 2019. Data were extracted from electronic medical records. Minor complications (partial-thickness wound dehiscence or flap necrosis, or tissue expander/implant malposition) and major complications (full-thickness wound dehiscence or flap necrosis, capsular contracture, tissue expander/implant explantation, or unplanned reoperation or readmission) were compared between groups. Patient-reported outcomes using BREAST-Q questionnaires were also assessed. Results: One hundred five patients (181 breasts) were included. Mean ± SEM age and body mass index were 57.1 ± 10.4 years and 37.9 ± 5.8 kg/m2 for the Goldilocks-only group and 51.5 ± 1.1 years and 35.5 ± 0.4 kg/m2 for the Goldilocks with immediate breast reconstruction group, respectively. Median follow-up time was 15.1 months (interquartile range, 10.0 to 28.6 months). Overall, 96 breasts underwent the Goldilocks-only procedure and 85 Goldilocks with immediate breast reconstruction. Multivariable analyses revealed a higher rate of minor complications (adjusted hazard ratio, 2.83; 95 percent CI, 1.22 to 7.02) and major complications (adjusted hazard ratio, 2.26; 95 percent CI, 1.25 to 4.24) in the Goldilocks with immediate breast reconstruction group compared with the Goldilocks-only group, at any given time. Patient satisfaction was not statistically different between groups. Conclusions: The Goldilocks procedure is a feasible breast reconstructive option in obese patients; however, when it is performed with immediate breast reconstruction, it is associated with higher rates of complications. For patients with a body mass index of 40 kg/m2 or greater, the authors recommend the Goldilocks-only procedure or delayed reconstruction. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.